Home
>
US Stocks
>
Athersys Inc

Athersys Inc (ATHX)

$0.9741

-0.01

(-0.6%)▲

Market is closed - opens 7 PM, 05 Jun 2023

Insights on Athersys Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 31.0K → 32.0K (in $), with an average increase of 3.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, -23.64M → -12.40M (in $), with an average increase of 27.7% per quarter

  • Vs SGEN

    In the last 1 year, Seagen Inc has given 39.6% return, outperforming this stock by 123.6%

  • Vs MRNA

    In the last 3 years, Moderna Inc has given 26.0% return, outperforming this stock by 124.7%

Performance

  • $0.93
    $1.03
    $0.97
    downward going graph

    3.62%

    Downside

    Day's Volatility :9.23%

    Upside

    5.83%

    downward going graph
  • $0.50
    $10.50
    $0.97
    downward going graph

    48.13%

    Downside

    52 Weeks Volatility :95.21%

    Upside

    90.76%

    downward going graph

Returns

PeriodAthersys IncSector (Health Care)Index (Russel 2000)
3 Months
-36.33%
0.9%
-8.3%
6 Months
60.0%
-6.8%
-6.5%
1 Year
-83.97%
0.4%
-6.1%
3 Years
-98.66%
27.3%
21.8%

Highlights

Market Capitalization
20.5M
Book Value
- $1.68
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-4.02
PEG Ratio
-0.34
Wall Street Target Price
5.5
Profit Margin
0.0%
Operating Margin TTM
-2151.26%
Return On Assets TTM
-97.44%
Return On Equity TTM
-1276.02%
Revenue TTM
2.4M
Revenue Per Share TTM
0.17
Quarterly Revenue Growth YOY
-95.7%
Gross Profit TTM
-65.6M
EBITDA
-50.7M
Diluted Eps TTM
-4.02
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.05
EPS Estimate Next Year
-0.7
EPS Estimate Current Quarter
-0.54
EPS Estimate Next Quarter
-0.48

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Athersys Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
00
Hold
1
1
2
Sell
00
00
4

Analyst Forecast

What analysts predicted

Upside of 464.62%

Current $0.97
Target $5.50

Company Financials

FY17Y/Y Change
Revenue
3.7M
↓ 78.62%
Net Income
-32.2M
↑ 110.22%
Net Profit Margin
-869.5%
↓ 781.09%
FY18Y/Y Change
Revenue
24.3M
↑ 555.1%
Net Income
-24.3M
↓ 24.68%
Net Profit Margin
-99.97%
↑ 769.53%
FY19Y/Y Change
Revenue
5.6M
↓ 76.81%
Net Income
-44.6M
↑ 83.59%
Net Profit Margin
-791.44%
↓ 691.47%
FY20Y/Y Change
Revenue
1.4M
↓ 74.44%
Net Income
-78.8M
↑ 76.67%
Net Profit Margin
-5.5K%
↓ 4678.35%
FY21Y/Y Change
Revenue
5.5K
↓ 99.62%
Net Income
-87.0M
↑ 10.4%
Net Profit Margin
-1.6M%
↓ 1571516.06%
FY22Y/Y Change
Revenue
5.3M
↑ 96472.36%
Net Income
-72.5M
↓ 16.58%
Net Profit Margin
-1.4K%
↑ 1575623.71%
Q4 FY21Q/Q Change
Revenue
-4.1K
↓ 184.93%
Net Income
-21.7M
↑ 34.21%
Net Profit Margin
533.4K%
↑ 871023.27%
Q1 FY22Q/Q Change
Revenue
2.9M
↓ 71647.91%
Net Income
-22.2M
↑ 2.33%
Net Profit Margin
-762.91%
↓ 534202.71%
Q2 FY22Q/Q Change
Revenue
2.3M
↓ 20.47%
Net Income
-23.6M
↑ 6.45%
Net Profit Margin
-1.0K%
↓ 258.16%
Q3 FY22Q/Q Change
Revenue
65.0K
↓ 97.19%
Net Income
-13.7M
↓ 42.2%
Net Profit Margin
-21.0K%
↓ 20008.16%
Q4 FY22Q/Q Change
Revenue
31.0K
↓ 52.31%
Net Income
-13.0M
↓ 4.89%
Net Profit Margin
-41.9K%
↓ 20909.48%
Q1 FY23Q/Q Change
Revenue
32.0K
↑ 3.23%
Net Income
-12.4M
↓ 4.59%
Net Profit Margin
-38.8K%
↑ 3176.21%
FY17Y/Y Change
Total Assets
33.6M
↑ 76.25%
Total Liabilities
10.2M
↑ 29.67%
FY18Y/Y Change
Total Assets
61.7M
↑ 83.76%
Total Liabilities
18.6M
↑ 82.19%
FY19Y/Y Change
Total Assets
41.7M
↓ 32.5%
Total Liabilities
18.4M
↓ 1.18%
FY20Y/Y Change
Total Assets
59.7M
↑ 43.32%
Total Liabilities
28.4M
↑ 54.13%
FY21Y/Y Change
Total Assets
60.2M
↑ 0.79%
Total Liabilities
43.8M
↑ 54.54%
FY22Y/Y Change
Total Assets
27.7M
↓ 53.92%
Total Liabilities
51.6M
↑ 17.73%
Q4 FY21Q/Q Change
Total Assets
60.2M
↓ 16.51%
Total Liabilities
43.8M
↑ 2.51%
Q1 FY22Q/Q Change
Total Assets
45.0M
↓ 25.3%
Total Liabilities
44.7M
↑ 1.91%
Q2 FY22Q/Q Change
Total Assets
35.2M
↓ 21.7%
Total Liabilities
46.9M
↑ 5.13%
Q3 FY22Q/Q Change
Total Assets
35.5M
↑ 0.96%
Total Liabilities
52.2M
↑ 11.11%
Q4 FY22Q/Q Change
Total Assets
27.7M
↓ 21.98%
Total Liabilities
51.6M
↓ 1.1%
Q1 FY23Q/Q Change
Total Assets
27.7M
↑ 0.0%
Total Liabilities
51.6M
↑ 0.0%
FY17Y/Y Change
Operating Cash Flow
-24.0M
↑ 119.72%
Investing Cash Flow
-285.0K
↓ 73.29%
Financing Cash Flow
38.9M
↑ 943.66%
FY18Y/Y Change
Operating Cash Flow
-13.4M
↓ 44.42%
Investing Cash Flow
-915.0K
↑ 221.05%
Financing Cash Flow
36.0M
↓ 7.35%
FY19Y/Y Change
Operating Cash Flow
-35.3M
↑ 164.61%
Investing Cash Flow
-579.0K
↓ 36.72%
Financing Cash Flow
19.9M
↓ 44.77%
FY20Y/Y Change
Operating Cash Flow
-61.8M
↑ 74.97%
Investing Cash Flow
-1.2M
↑ 100.69%
Financing Cash Flow
79.5M
↑ 299.64%
FY21Y/Y Change
Operating Cash Flow
-76.2M
↑ 23.26%
Investing Cash Flow
-1.4M
↑ 17.04%
Financing Cash Flow
63.4M
↓ 20.22%
Q4 FY21Q/Q Change
Operating Cash Flow
-19.3M
↓ 47.39%
Investing Cash Flow
-206.0K
↓ 47.98%
Financing Cash Flow
7.3M
↓ 83.06%
Q1 FY22Q/Q Change
Operating Cash Flow
-20.2M
↑ 4.31%
Investing Cash Flow
-186.0K
↓ 9.71%
Financing Cash Flow
4.7M
↓ 34.8%
Q2 FY22Q/Q Change
Operating Cash Flow
-16.4M
↓ 18.49%
Investing Cash Flow
-1.6M
↑ 781.18%
Financing Cash Flow
9.7M
↑ 103.58%
Q3 FY22Q/Q Change
Operating Cash Flow
-10.4M
↓ 36.83%
Investing Cash Flow
-178.0K
↓ 89.14%
Financing Cash Flow
11.0M
↑ 13.54%

Technicals Summary

Sell

Neutral

Buy

Athersys Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Athersys Inc
Athersys Inc
27.02%
60.0%
-83.97%
-98.66%
-98.56%
Moderna, Inc.
Moderna, Inc.
0.28%
-25.82%
-4.84%
117.92%
601.67%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.87%
-2.05%
17.39%
22.45%
137.1%
Seagen, Inc.
Seagen, Inc.
-1.61%
61.18%
39.62%
26.01%
217.64%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.63%
5.09%
23.88%
20.49%
123.04%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Athersys Inc
Athersys Inc
0.72
NA
-0.34
-1.05
-12.76
-0.97
0.0
-1.68
Moderna, Inc.
Moderna, Inc.
11.46
11.46
0.0
-1.9
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.91
19.91
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.18
26.18
0.41
14.61
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Athersys Inc
Athersys Inc
Buy
$20.5M
-98.56%
0.72
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$49.1B
601.67%
11.46
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$80.7B
137.1%
19.91
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.5B
217.64%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$83.3B
123.04%
26.18
35.4%

Institutional Holdings

  • Vahanian & Associates Financial Planning Inc.

    3.94%

  • BlackRock Inc

    2.20%

  • Vanguard Group Inc

    1.94%

  • Renaissance Technologies Corp

    0.43%

  • Geode Capital Management, LLC

    0.38%

  • SIMPLEX TRADING, LLC

    0.34%

Company Information

Athersys is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived 'off-the-shelf' stem cell product, initially for disease indications in the neurological, inflammatory and immune, cardiovascular, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance the MultiStem cell therapy toward commercialization.

Organization
Athersys Inc
Employees
24
CEO
Mr. Daniel A. Camardo M.B.A.
Industry
Health Technology

Discover More

FAQs